AVBP
ArriVent BioPharma, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
ArriVent BioPharma has 8 disclosed suppliers and 0 disclosed customers in SEC filings.
Last report0 of 6 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−4.64%
vs ±16.3% implied · ×0.29
shaded = implied · ▲▼ = realized
ArriVent BioPharma, Inc.
14.93
−1.02 · −6.41%
post 14.72 −1.39%
SentenceAlso in 2021, we entered into a research collaboration, as amended, with Aarvik Therapeutics, Inc. (Aarvik) to leverage its proprietary multi-target, multivalent, site-specific conjugation antibody platform to discover next-generation antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs.
AVBP 10-Kaccession 0001104659-26-024127
SentenceOn June 23, 2023, we entered into a Clinical Collaboration Agreement (the InnoCare Collaboration Agreement) with InnoCare, pursuant to which we and InnoCare agreed to contribute resources to a clinical trial evaluating the use of firmonertinib in combination with InnoCare's ICP-189, a SHP2i (the InnoCare Collaboration Clinical Trial).
AVBP 10-Kaccession 0001104659-26-024127
SentenceIn 2024, we entered into a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (Alphamab), a wholly owned subsidiary of Alphamab Oncology, to discover, develop and commercialize novel ADCs for the treatment of cancers globally, with the exception of greater China, which includes mainland China, Hong Kong, Macau and Taiwan.
AVBP 10-Kaccession 0001104659-26-024127
SentenceWe have entered into the Lepu Biopharma Agreement, pursuant to which, we have, among other things, secured an exclusive, royalty bearing and sublicensable license under certain intellectual property, including patents and know-how, owned or controlled by Lepu Biopharma to develop and commercialize any product containing ARR-217 or the antibody component of ARR-217.
AVBP 10-Kaccession 0001104659-26-024127
SentenceIn 2021, we licensed from Allist the right to develop and commercialize firmonertinib worldwide, with the exception of greater China, which includes mainland China, Hong Kong, Macau and Taiwan.
AVBP 10-Kaccession 0001104659-26-024127
SentenceCurrently, we rely on, and have agreements with, two third-party contract manufacturers, Zhejiang Raybow Pharmaceutical Company., Ltd. (Raybow) and SynTheAll Pharmaceutical Co., Ltd. (WuXi STA) to supply the drug substance for firmonertinib to be used in on-going and planned clinical trials and with WuXi STA, with whom we have executed technology transfer related to the manufacture of drug product, to manufacture the clinical trial and initial commercial launch supplies of firmonertinib drug product.
AVBP 10-Kaccession 0001104659-26-024127
SentenceWe expect to rely on manufacturers in China for ARR-217 drug substance and drug product for use in initial clinical studies and also expect to rely on WuXi XDC Cayman, Inc., (WuXi XDC) for the manufacture of ARR-002 drug product and drug substances for initial clinical studies.
AVBP 10-Kaccession 0001104659-26-024127
SentenceCurrently, we rely on, and have agreements with, two third-party contract manufacturers, Zhejiang Raybow Pharmaceutical Company., Ltd. (Raybow) and SynTheAll Pharmaceutical Co., Ltd. (WuXi STA) to supply the drug substance for firmonertinib to be used in on-going and planned clinical trials and with WuXi STA, with whom we have executed technology transfer related to the manufacture of drug product, to manufacture the clinical trial and initial commercial launch supplies of firmonertinib drug product.
AVBP 10-Kaccession 0001104659-26-024127
—
—
Largest filed tie
—
Expected move
No implied move.